Led · Equity · Jan 2019

EarlySense, led by CEO Avner Halperin, develops contact-free continuous monitoring solutions used worldwide across the care continuum. Its FDA-cleared and CE-approved systems are deployed in hospitals, post-acute facilities and homes to assist clinicians in early detection of patient deterioration. The technology leverages artificial intelligence and big data analytics to deliver actionable health insights. EarlySense says its solutions have been proven to help prevent adverse events including code blue events, preventable ICU transfers, patient falls, pressure ulcers and hospital readmissions. The company is headquartered in Ramat Gan, Israel and Woburn, Massachusetts, and recently completed a $39M financing round. EarlySense provides an FDA-cleared and CE-approved contact-free continuous monitoring system that tracks patient heart rate, respiratory rate and movement via a sensor placed under the mattress. Continuous data is displayed on bedside monitors, nurse monitoring stations and delivered to clinicians’ smart devices. The company’s technology leverages Big Data and advanced algorithms to generate accurate health information for early detection of adverse events and improved patient outcomes. Its sensor technology also powers consumer products including Samsung’s SleepSense, iFit’s Sleep Sensor and Beurer’s SE 80 Sleep Expert. The company intends to use the new funding to continue to grow and to launch consumer digital health offerings based on its proven technology. EarlySense was founded in 2004 and is led by CEO Avner Halperin, with operations in Waltham, MA and Ramat Gan, Israel. EarlySense has developed a platform based on algorithms, analytics and smart Health/IT capabilities for contact-free, continuous monitoring of heart and respiratory rate, as well as movement and sleep. The system is installed in hospitals, rehabilitation centers and homes across the USA, Europe, Asia and Australia. EarlySense also offers OEM solutions for companies looking to add contact-free and continuous sensing capabilities to their products. The company is led by CEO Avner Halperin and has US headquarters in Waltham, MA while being based in Ramat Gan, Israel. EarlySense completed a $20M financing and intends to use the funds to continue to expand operations. EarlySense is described as the market leader in proactive patient care solutions, with a flagship contact‑free system that monitors and documents patients' vital signs and movement via a sensor placed beneath a mattress. The system requires no leads or cuffs, allowing patients freedom of movement, and is designed primarily for non‑ICU 'lower risk' patients on medical‑surgical floors. EarlySense's technology is installed in hospitals and rehabilitation centers across the U.S. and Europe and is commercially available in Canada. The company plans to use new financing to accelerate sales, further develop its contact‑free monitoring solutions, expand clinical research, and support global commercialization efforts. EarlySense is headquartered in Waltham, MA. EarlySense commercializes an automatic, continuous, contact-free patient monitoring system that documents vital signs and movement without leads or cuffs. The system is installed in hospitals and rehabilitation centers in the USA and Europe and is commercially available in Canada. Management and new board member Peter Soderberg see opportunities for rapid market growth initially in hospital and long‑term care markets and subsequently in the home market. The company recently received new innovative technology status from Novation and published clinical results from a Dignity Health study with Harvard‑affiliated support showing improved clinical outcomes. EarlySense is headquartered in Waltham, MA and lists investors including JK&B, Pitango Venture Capital, Etgar Challenge Fund, ProSeed VC Fund (TASE: PRSD), Docor International Management, Noaber, and Bridge Investment Fund. The press release does not disclose operating metrics such as revenue or user counts.